Immutep Ltd ADR (IMMP)

Immutep Ltd ADR (IMMP) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $32.1M; returns 1 day +0.9%, 1 week +0.0%, 1 year -92.0%.

Immutep Ltd is a late clinical-stage biotechnology company headquartered in Australia, specializing in the development of novel immunotherapies for both cancer and autoimmune diseases. Their core scientific focus is on Lymphocyte Activation Gene-3 (LAG-3), an immune checkpoint molecule crucial for regulating the immune system.

Groups IMMP belongs to

• Biotechnology
• Recent Reverse Splits
• Immunotherapy
• Healthcare
• Clinical Stage Biotech
• Life Sciences
• Oncology
• Clinical Stage
• Cancer Therapeutics
• Autoimmune Diseases
• Biopharmaceutical
• R&D

IMMP financial model: income statement, cash flow and balance sheet